AI has evolved from a promising innovation to a transformational force in pharmaceutical R&D, manufacturing and supply chain optimisation. But as the industry moves beyond early adoption, the big questions remain—how effective is AI in practice, and where are the real opportunities for impact?

How can pharmaceutical businesses ensure they are integrating necessary digital and data infrastructure effectively? More importantly, how does this translate into tangible benefits for quality, compliance and operational efficiency, whilst remaining sustainable?

As the industry faces mounting pressure to boost efficiency, minimise waste and strengthen supply chain resilience, process intensification is emerging as a game-changer for pharma manufacturing. This panel will explore how advanced process technologies, from continuous manufacturing to micro-factories, are reshaping production. But what are the barriers to widespread adoption, and how can the industry navigate the challenges ahead?

Some advanced therapies are produced with highly labour-intensive but repetitive processes. Automated manufacturing is promising to deliver dramatic productivity and reproducibility improvements, along with significant enhancements to return of capital, but will it deliver? What role can robotics play in the production of pharmaceuticals of the future?

The concept of truly personalised therapies is often talked about but seldom delivered. How can emergent pharma technologies support the delivery of truly tailored therapies, to bring outstanding patient outcomes?